ArticleDiscover oncology2026
Comprehensive bioinformatics analysis targeting sphingosine-related genes in head and neck cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A comprehensive bioinformatics analysis of the expression of sphingosine-related genes and prognosis of patients with head and neck squamous cell carcinoma (HNSCC) was performed using TCGA data and TIMER. A keyword search using sphingosine identified 29 genes, 10 of which were associated with patient survival. The expression of CERS2, CERS5, PLPP3, SGPP1, and S1PR4 significantly differed between tumors and normal tissue. A protein-protein interaction analysis revealed a dense network of these genes. Survival rates decreased in patients with the high expression of CERS2, CERS5, and SGPP1, and increased in those with the high expression of PLPP3 and S1PR4. An examination of the relationship between the expression of these five genes and classical clinical risk factors revealed that the high expression of CESR5 negatively correlated with survival for all classical clinical risk factors, while that of S1PR4 positively correlated with survival. The TIMER analysis showed that CERS5 and S1PS4 expression on tumor-infiltrating immune cells from HNSCC patients was associated with survival. Collectively, these results indicate the potential of CERS5 as a marker of a poor prognosis, and the contribution of S1PR4 to a favorable prognosis through its expression on immune cells. Therefore, the expression of sphingosine-related genes on tumor cells and infiltrating immune cells is important for the prognosis of HNSCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.